热门出版物 - 学术资源搜索

h5 指数:77
h5 中位数:131

h5 指数是指在过去整整 5 年中所发表文章的 h 指数。h 指在 2018-2022 年间发表的 h 篇文章每篇至少都被引用过 h 次的最大值。隐藏

出版物的 h5 中位数，是指出版物的 h5 指数所涵盖的所有文章获得的引用次数的中位值。隐藏

#8 Hematology

标题/作者	引用次数	年份
Coagulation abnormalities and thrombosis in patients with COVID-19 M Levi, J Thachil, T Iba, JH Levy The Lancet Haematology 7 (6), e438-e440	1499	2020
Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study G Goshua, AB Pine, ML Meizlish, CH Chang, H Zhang, P Bahel, A Baluha, ... The Lancet Haematology 7 (8), e575-e582	970	2020
Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study D Liao, F Zhou, L Luo, M Xu, H Wang, J Xia, Y Gao, L Cai, Z Wang, P Yin, ... The Lancet Haematology 7 (9), e671-e678	482	2020
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study F Passamonti, C Cattaneo, L Arcaini, R Bruna, M Cavo, F Merli, ... The Lancet Haematology 7 (10), e737-e745	477	2020
Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19 T Wang, R Chen, C Liu, W Liang, W Guan, R Tang, C Tang, N Zhang, ... The Lancet Haematology 7 (5), e362-e363	438	2020
Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation O Penack, M Marchetti, T Ruutu, M Aljurf, A Bacigalupo, F Bonifazi, ... The Lancet Haematology 7 (2), e157-e167	308	2020
Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study SW Pipe, M Shima, M Lehle, A Shapiro, S Chebon, K Fukutake, NS Key, ... The Lancet Haematology 6 (6), e295-e305	280	2019
Effects of the COVID-19 pandemic on supply and use of blood for transfusion SJ Stanworth, HV New, TO Apelseth, S Brunskill, R Cardigan, C Doree, ... The Lancet Haematology 7 (10), e756-e764	270	2020
Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study A Sharma, NS Bhatt, A St Martin, MB Abid, J Bloomquist, RF Chemaly, ... The Lancet Haematology 8 (3), e185-e193	266	2021
Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study M Cavo, F Gay, M Beksac, L Pantani, MT Petrucci, MA Dimopoulos, ... The Lancet Haematology 7 (6), e456-e468	247	2020
A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts I Pabinger, N van Es, G Heinze, F Posch, J Riedl, EM Reitter, M Di Nisio, ... The Lancet Haematology 5 (7), e289-e298	244	2018
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial CN Harrison, AM Vannucchi, U Platzbecker, F Cervantes, V Gupta, ... The Lancet Haematology 5 (2), e73-e81	222	2018
A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial Z Yan, J Cao, H Cheng, J Qiao, H Zhang, Y Wang, M Shi, J Lan, X Fei, ... The Lancet Haematology 6 (10), e521-e529	222	2019
Epidemiological patterns of leukaemia in 184 countries: a population-based study A Miranda-Filho, M Piñeros, J Ferlay, I Soerjomataram, A Monnereau, ... The Lancet Haematology 5 (1), e14-e24	219	2018
Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial A Ahmed, SA Merrill, F Alsawah, P Bockenstedt, E Campagnaro, ... The Lancet Haematology 6 (12), e630-e637	216	2019
Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study K Maneikis, K Šablauskas, U Ringelevičiūtė, V Vaitekėnaitė, ... The Lancet Haematology 8 (8), e583-e592	215	2021
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial N Kalakonda, M Maerevoet, F Cavallo, G Follows, A Goy, JSP Vermaat, ... The Lancet Haematology 7 (7), e511-e522	215	2020
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study H Gisslinger, C Klade, P Georgiev, D Krochmalczyk, ... The Lancet Haematology 7 (3), e196-e208	206	2020
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study E Jabbour, NJ Short, F Ravandi, X Huang, N Daver, CD DiNardo, ... The Lancet Haematology 5 (12), e618-e627	194	2018
Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial Y Shi, H Su, Y Song, W Jiang, X Sun, W Qian, W Zhang, Y Gao, Z Jin, ... The Lancet Haematology 6 (1), e12-e19	191	2019

1 - 20

计算机程序会自动估算并确定日期和引用次数。